News | April 15, 2013

First Implant Performed for AigisRx R Fully Resorbable Antibacterial Envelope

AigisRX Antibacterial Envelope Tryx Infection Control

April 15, 2013 — Tyrx announced the first implantation of its new AigisRx R Fully Resorbable Antibacterial Envelope has taken place at the Quebec Heart and Lung Institute in Quebec City, Canada by Dr. François Philippon. Tyrx announced on Jan. 31, 2013 that it had received a license from Health Canada to market its AigisRx R Fully Resorbable technology.

The AigisRx R Antibacterial Envelope is specifically designed to stabilize electronic implantable devices (EIDs), such as pacemakers and defibrillators, while also releasing antimicrobial agents to help provide protection from microbial colonization of the device during surgical implantation.

“Surgical site infections are on the rise and have profound consequences to the patient with regard to having to spend extra time in the hospital, having to undergo additional surgical procedures, and having significant increases in morbidity and mortality. They are also very expensive to treat,” stated Philippon, cardiac electrophysiologist at the Quebec Heart and Lung Institute. “I found implantation of the fully resorbable envelope to be very straightforward and believe that the combination of stabilization and locally delivered antibiotics provided by the product will be of great potential benefit to our patients.”

“We are very excited to have the world’s first AigisRx R Antibacterial Envelope implanted at the Quebec Heart and Lung Institute,” commented Robert White, Tyrx president and chief executive officer. “The AigisRx R includes all of the advantages of the original AigisRx, such as stability and infection reduction, but now with the added benefit of full resorption in approximately nine weeks.”

The AigisRx R Envelope is intended to hold the EIDs, such as pacemakers and implantable cardioverter defibrillators (ICDs), securely in place in order to provide a stable environment when implanted in the body. Additionally, the AigisRx R contains the antimicrobial agents rifampin and minocycline, which are released over a minimum of seven days in order to help provide protection from microbial colonization of the device during surgical implantation.

For more information: www.TYRX.com, www.HeartDeviceInfection.com.

Related Content

Seth Worley, M.D., senior consultant, section of cardiac electrophysiology, MedStar Heart and Vascular Institute, developed tools and techniques to optimize transvenous left ventricular (LV) lead implantation, including the I-CRT approach. Here he holds the tools that he personally developed for left ventricular lead implantation to treat heart failure. Photo courtesy of MedStar Heart and Vascular Institute at MedStar Washington Hospital Center.

Seth Worley, M.D., senior consultant, section of cardiac electrophysiology, MedStar Heart and Vascular Institute, developed tools and techniques to optimize transvenous left ventricular (LV) lead implantation, including the I-CRT approach. Here he holds the tools that he personally developed for left ventricular lead implantation to treat heart failure. Photo courtesy of MedStar Heart and Vascular Institute at MedStar Washington Hospital Center.

Feature | EP Lab | January 21, 2019 | Matthew S. McKillop, M.D., FACC, FHRS, and Seth J. Worley, M.D.
Interventional...
An implanted ICD showing its three venous leads. These multiple CRT leads can cause issues when they need to be replaced and are abandoned with new leads put over them in the SVC, which may require lead extraction.

An implanted ICD showing its three leads in the venous system. 

Feature | EP Lab | January 13, 2019 | Dave Fornell, Editor
To extract or abandon broken or infected implantable, venous...
Videos | EP Lab | January 03, 2019
This is a quick video tour of one of the dedicated...
HHS and NASA Team Up to Explore Health on Earth and in Outer Space

Image courtesy of NASA

News | EP Lab | December 14, 2018
The Department of Health and Human Services (HHS) recently entered into an interagency agreement with the National...
Technology Improvements Driving Electrophysiology Market Growth

Navik 3D Cardiac Mapping System image courtesy of APN Health.

News | EP Lab | December 10, 2018
December 10, 2018 — Electrophysiology, whil
Vagal Maneuvers With Supraventricular Tachycardia

Image courtesy of ACLS Certification Institute

Feature | EP Lab | December 05, 2018
Supraventricular tachycardia (SVT) is a common heart abnormality that presents as a fast heart rate. SVT is a generic...
Societies Publish New Guidance for Treatment of Slow, Irregular Heartbeats
News | EP Lab | November 09, 2018
The American College of Cardiology (ACC), the American Heart Association (AHA) and the Heart Rhythm Society (HRS)...
A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

News | EP Lab | June 05, 2018
June 5, 2018 — Philips Healthcare has signed an agreement to acquire EPD Solutions, a provider of image-guidance in c
A recent study shows the Baylis NRG radiofrequency (RF) Transseptal puncture catheter has a lower incidence of embolism in EP cases.
News | EP Lab | May 21, 2018
May 21, 2018 — A recent study published in Heart and Vessels has found that the use of the Baylis Medical NR
Overlay Init